Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374731 | 0.91 | IGF1R (0.41) | IGF1RTSHRKDM4EMAPTKMT2A | |
| SCHEMBL1372185 | 0.87 | IGF1R (0.49) | IGF1RNTRK1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1375199 | 0.86 | NTRK1 (0.33) | IGF1RNTRK1USP2 | |
| SCHEMBL1374766 | 0.84 | IGF1R (0.33) | IGF1RNTRK1KDM4EMAPTKMT2A | |
| SCHEMBL1374585 | 0.83 | MAPT (0.33) | IGF1RNTRK1MAPTKMT2AUSP2 | |
| SCHEMBL4280826 | 0.81 | — | — | |
| SCHEMBL1373122 | 0.80 | IGF1R (0.54) | IGF1RNTRK1 | |
| SCHEMBL1371564 | 0.79 | SMN1; SMN2 (0.37) | IGF1RTSHRKDM4EMAPTKMT2A | |
| SCHEMBL1373008 | 0.79 | SMN1; SMN2 (0.34) | IGF1RTSHRKDM4EMAPTKMT2A | |
| SCHEMBL1372652 | 0.79 | USP2 (0.34) | IGF1RTSHRKDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461193-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-11 | — | — | US | disclosed |
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.I. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7968583-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-06-25 | — | — | US | disclosed |
| EP-1963326-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068637-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885NTRK1 1363/4885TSHR 2801/4885 |
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885NTRK1 1363/4885TSHR 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.